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SUMMARY
Five cases of secondary anti-phospholipid syndrome (APS) are presented and 
literature reviewed. Pregnancy loss was the most common presentation but neurologic 
manifestations are also seen. IgG ACA was more commonly seen than IgM ACA. 
Although APS has been infrequently reported in black Africans, an awareness of 
this condition is needed especially among females with previous recurrent pregnancy 
losses. 
INTRODUCTION
Anti-phospholipid syndrome (APS, Hughes 
Syndrome) is  an acquired, autoimmune 
thrombophilia, usually associated with significant 
morbidity and mortality. The diagnosis requires 
clinical manifestations of recurrent arterial and 
venous thrombosis: recurrent pregnancy losses, as 
well as the demonstration of serum anti-phospholipid 
antibodies (APA) (1).
 APS could either be primary or secondary to 
connective tissue diseases such as systemic lupus 
erythematosus, polymyositis, scleroderma, and 
inflammatory arthritis like rheumatoid arthritis. It 
could also be associated with infectious diseases and 
neoplasms (2).
 Clinical manifestations may also include 
thrombocytopoenia, livedo reticularis, cutaneous 
necrosis, haemolytic anaemia, heart valvular disease, 
chorea, migraine, foetal growth retardation and pre-
eclampsia. 
 A particularly severe form is catastrophic 
anti-phospholipid syndrome (CAPS) which is 
characterised by widespread microthrombi, in 
multiple vascular beds culminating in fulminant 
multiple organ failure. Organ manifestations in 
CAPS may include renal impairment, abnormal liver 
enzymes and failure as well as respiratory failure and 
adrenal insufficiency (3).
 Anti-phospholipid antibodies are found in 1-5% 
of young healthy subjects with the frequency rising 
with age and presence of co-existent chronic diseases. 
Prevalence of these antibodies among SLE patients is 
about 12-30% for anti-cardiolipin antibodies (ACA) 
and 15-34% for lupus anticoagulant (LAC) (4,5). It 
has been suggested that the lupus anticoagulants 
are immunologically distinct from ACA; though the 
associated clinical complications exhibited by the two 
groups of antibodies are similar (6,7).  
 It has been shown that the binding of anti-
phospholipid antibodies to cellular phospholipids 
requires the serum co-factor, beta-2 glycoprotein 1. 
Among patients with SLE selected for the presence 
of lupus anticoagulant, thrombosis or foetal loss, 
36% had anti-beta 2 glycoprotein 1. The effect of this 
protein has been associated with inhibitory effects on 
platelet aggregation, platelet thrombokinase activity 
as well as the intrinsic pathway of coagulation. These 
further support the hypothesis that implicates this 
protein in the pathogenesis of unwanted thrombotic 
events (8). 
 Systemic lupus erythematosus is not commonly 
reported among black Africans (9) and associated 
APS has rarely been reported. The objective of this 
case is to show the presentation and management of 
APS among Nigerians. 
 We hereby present five patients with Anti-
phospholipid syndrome among 66 diagnosed SLE 
patients seen in a private practice rheumatology 
clinic. 
CASE REPORTS
Case  1: Mrs. M. O., a 34 year old female who 
presented with photosensitivity rash; polyarthritis 
of the shoulder, elbows, hands, ankles associated 
with joint morning stiffness; generalised macular 
body rashes; pleuritic chest pain; and two previous 
abortions at 18 and 20 weeks. Physical examination 
showed a young lady with marked tenderness in 
most of the joints. Respiratory system examination 
showed pleural rubs at the right basal region. 
 Laboratory investigations - Urine dispstick 
showed proteinuria of 2+, no casts, no haematuria. 
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Haematocrit was 39% with normal white blood cell 
count and differentials. Erythrocyte sedimentation rate 
- 106 (Westergren mm/hr). Serum urea - 20.5mg/dl.
 Serology - Rheumatoid factor 25(normal 0-
20); anti nuclear antibody - 320 (normal 0-40): 1 gG 
Cardiolipin - 44gpl/ml (normal 0-15); I gM cardiolipin 
6.4mpl/ml (normal 0-13.5). 
 The diagnosis was SLE with APS. She was treated 
with methotrexate tablets - 15mg once weekly, aspirin 
tablets - 75mg daily and prednisolone tablets - 15mg 
daily. She is still being followed up. 
Case 2: Mrs. E. U; a 28 year old female who presented 
with generalised urticaria rashes- nine months 
before presentation; pruritic maculo papular rashes 
on the trunk and face and polyarthralgia affecting 
joints of the hands, ankles and knee. Physical 
examinations showed a young, cachetic lady with 
maculo papular rashes on the trunk and face. She 
also had tenderness of the metacarpophalangeal and 
proximal interphalangeal, wrist joints of both hands 
as well as the knees. 
 Laboratory investigations - white blood cell 
count- 3,800 (neutrophils - 86%; lymphocytes - 14%). 
Platelet count showed thrombocytopenia - 87,000 
per cu.mm.  Serum urea was normal- 16.8 mg/dl. 
Serology - ANA positive 1: 5120 speckled pattern; 
Anti RNP positive; anti DNA - negative. 1gM anti 
cardiolipin - 54.2mplml (0-13.5). Diagnosis was 
SLE. She was placed on azathioprine 100 mg daily 
and prednisolone tablets - 10mg daily. About two 
years after presentation, she became pregnant but 
had a miscarriage at 22 weeks. Examination of the 
placenta by the obstetrician showed a small placenta 
with areas of infarction. Additional diagnosis of anti-
phospholipid syndrome was made. 
Case 3: Mrs. J. N., a 29 year old diagnosed SLE. She 
presented with a flare up of polyarthralgia, fatigue, 
malar rashes and fever. History also revealed that she 
has had a previous miscarriage at sixteen weeks. 
 Physical examination revealed that she 
was febrile and had macular and malar rashes. 
Examination of oilier systems were essentially normal. 
Blood pressure was 110/80mmHg. 
 Laboratory investigations - haematocrit - 38%; 
white blood cell count 6,800/cu.mm with normal 
differentials. Erythrocyte sedimentation rate was 
86mm/hour. 
 Serology - ANA positive 1:80 (speckled pattern); 
IgG cardiolipin antibody 42.9gp/ml (0-15); IgM 
cardiolipin antibody - 4.8mpl/ml (0-13.5).
 Diagnosis of SLE and elevated Anti- 
phosphol ipids  antibody was made.  She 
became pregnant later and was continued on 
hydroxychloroquine, prednisolone and aspirin. 
In addition, she was placed on subcutaneous low 
molecular weight heparin, (enoxaparin). Heparin 
and aspirin were discontinued at 34 weeks cyesis. 
She had a normal, uneventful delivery at 38 weeks 
and is still being followed up. 
Case 4: Mrs. E. E., a 36 year old female who presented 
with polyarthralgia; recurrent fever; loss of weight; 
hyperpigmented macular rashes on the limbs and 
trunk; progressive weakness of lower limbs. 
 Physical examination showed a young lady 
with hyperpigmented rashes on both lower limbs 
as well as hepatomegaly of 6cm. Blood pressure was 
126/84mmHg. Central nervous system examination 
revealed weakness in both lower limbs with muscle 
power Grade III. Tendon reflexes were brisk and 
there was Babinski response on plantar reflex. There 
was no sensory loss. Laboratory investigations - 
haematocrit - 40%, white blood cell count 5,600 per 
cu.mm with normal differentials. Platelet count was 
230,000 per cu.mm. Erythrocyte sedimentation rate 
- 120mm/hour. Serum Urea - 44.3 (l 0.50); creatinine 
kinase - 48 (1 0-70); urine analysis and microscopy 
were normal. Serology showed ANA titre of 1:320 
(0-39) homogeneous pattern; ENA positive, Anti-
DNA negative; lgG cardiolipin antibody-77.0gpl/ml 
(0-15); 1gM cardiolipin antibody-119mp/ml (0-13.5). 
 Diagnosis  was SLE myelopathy and 
antiphospholipid syndrome. She was placed on 
azathioprine, prednisolone, aspirin and warfarin. 
She was also started on physical therapy. She is still 
being followed up. 
Case 5: O.O was a 24 year old female who presented 
with polyarthralgia; recurrent sore throat and mouth 
ulcers; hair loss; recurrent temporal headaches. She 
has had both pleural and pericardial effusion before 
presentation for which anti-tuberculous drugs had 
been initiated elsewhere Physical examination 
showed a cachetic lady, slightly pale. Pulse was 120 
beats per minutes. Blood pressure was 110/70mmHg. 
Chest examination revealed bilateral dullness 
to percussion and reduced breath sounds in the 
lower and middle chest zones. Other systems were 
essentially normal. 
 Laboratory investigations - elevated erythrocyte 
sedimentation rate - 80mm/hour. Dipstick urine 
examination showed albuminuria - 3+ with pus 
and epithelial cells. Serology - anti nuclear antibody 
- 1:1280 (speckled). IgM ACA-41.6 mpl/ml(0-13.5). 
IgGgpl/ml ACA-30 (0-15).
 Treatment  was ini t iated with pulse 
methylprednisolone, azathioprine and aspirin. 
 A week following initiation of medications, she 
had two episodes of seizure and thereafter, became 
weak in both lower limbs. Central nervous system 
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examination showed hypereflexia in both lower limbs 
as well as Babinski response on plantar reflex. 
 Diagnosis was SLE with myelopathy from 
anti-phospholipid syndrome. She was placed 
on low molecular weight heparin and warfarin. 
Physiotherapy was also initiated. She is still being 
followed up. 
DISCUSSION
The five cases presented represent part of the spectrum 
of anti-phospholipid syndrome. All the cases were 
secondary to SLE. Three of the cases had presented 
with pregnancy losses at one time or the other while 
the remaining two had neurological manifestations. 
Recurrent pregnancy losses among those affected 
could be particularly distressing. In many cases, 
unnecessary investigations are carried out all to no 
avail. An awareness and effective management of 
this syndrome could prevent this, especially in those 
with primary APS. 
 Neurological manifestations are among the 
most common presentation in APS and includes 
cerebral ischaemia, cognitive dysfunction, dementia, 
psychosis, depression, seizures, chorea and 
myelopathy (10). This was corroborated in a study 
by Miesbach et al (11) which showed a prevalence of 
antiphospholipid antibody in 15% of 350 unselected 
patients attending a neurology clinic. 
 1gG ACA was elevated in four of the patients 
while 1gM ACA was elevated in three patients. Both 
antibodies were elevated in two cases, both of whom 
had neurological manifestations. 
 1gA anti cardiolipin antibodies have been 
reported to be the most prevalent among African 
Americans with APS (12). However, this test was not 
performed in our patients. Secondary APS, though 
rarely reported among black Africans, should be 
considered in patients presenting with unexplained 
recurrent abortions and neuropsychiatric lupus. 
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